Cargando…
Computational investigation into Nirematrelvir/Ritonavir synergetic efficiency compared with some approved antiviral drugs targeting main protease (M(pro)) SARS-CoV-2 Omicron variant
Although the severity of the spread of corona virus has recently decreased. On this day, there is no available effective medication established to treat COVID-19. Combination drug therapy has been recently gained new momentum as an important platform to design and develop several anti-infective agen...
Autores principales: | Makhloufi, Abdesselam, Ghemit, Rima, El Kolli, Meriem, Baitiche, Milad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Indian Chemical Society. Published by Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850841/ http://dx.doi.org/10.1016/j.jics.2023.100891 |
Ejemplares similares
-
Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022) -
In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021) -
Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022) -
An in-silico evaluation of COVID-19 main protease with clinically approved drugs
por: Tachoua, Wafa, et al.
Publicado: (2020) -
Repurposing of US-FDA approved drugs against SARS-CoV-2 main protease (M(pro)) by using STD-NMR spectroscopy, in silico studies and antiviral assays
por: Khan, Abdul Mateen, et al.
Publicado: (2023)